The Laboratory core will provide sample preparation, storage, and laboratory assays for all four projects of the program project. A major goal of this core will be centralized sample processing, storage and retrieval, and most importantly, standardized assays of relevant specimens. As part of this goal, the core will expedite sample retrieval and data recording to encourage full utilization of the unique clinical specimens obtained during these studies. The core will provide both conventional serologic assays and solid phase RIA for measurement of antigen specific responses. A seroconversion EIA and confirmatory western blt has been modified for this study and will allow rapid and accurate determination of seroconversion in participants of the vaccine trial. As part of the effort to standardize assays and insure accurate analysis of samples from the various projects, the core will be responsible for assaying large numbers of serum specimens for virus neutralizing activity. Virus shredding will be detected by both conventional methods and rapid screening procedures, and virus excretion quantitated in patients identified in Projects 3. Finally, the core laboratory will also re responsible for the PCR detection of HCMV nucleic acids. The PCR assays will include a screening qualitative amplification followed by a quantitative competitive PCR. Quality control of the various assays performed in this core will be assured by close supervision of the laboratory direction and co-director. The laboratory core is well integrated into all of the projects described in this program because it serves as the central laboratory for each of the projects. Providing high quality laboratory support and sample storage is essential to successful completion of the overall goal of this program project.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
United States
Zip Code
Pinninti, Swetha G; Rodgers, Mackenzie D; Novak, Zdenek et al. (2016) Clinical Predictors of Sensorineural Hearing Loss and Cognitive Outcome in Infants with Symptomatic Congenital Cytomegalovirus Infection. Pediatr Infect Dis J 35:924-6
Dreher, A Mackenzie; Arora, Nitin; Fowler, Karen B et al. (2014) Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr 164:855-9
Hackett, Daniel J; Zhang, Changpin; Stefanescu, Carla et al. (2010) Enzyme-linked immunosorbent assay for measurement of cytomegalovirus glycoprotein B antibody in serum. Clin Vaccine Immunol 17:836-9
Pass, Robert F (2009) Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J Clin Virol 46 Suppl 4:S73-6
Pass, Robert F; Zhang, Changpin; Evans, Ashley et al. (2009) Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360:1191-9
Ross, Shannon A; Novak, Zdenek; Fowler, Karen B et al. (2009) Cytomegalovirus blood viral load and hearing loss in young children with congenital infection. Pediatr Infect Dis J 28:588-92
Ross, Shannon A; Novak, Zdenek; Kumbla, Rekha A et al. (2007) GJB2 and GJB6 mutations in children with congenital cytomegalovirus infection. Pediatr Res 61:687-91
Pass, Robert F; Fowler, Karen B; Boppana, Suresh B et al. (2006) Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J Clin Virol 35:216-20
Fowler, Karen B; Boppana, Suresh B (2006) Congenital cytomegalovirus (CMV) infection and hearing deficit. J Clin Virol 35:226-31
Zhang, Changpin; Buchanan, Hannah; Andrews, William et al. (2006) Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding. J Clin Virol 35:338-42

Showing the most recent 10 out of 24 publications